uniQure N.V.
http://www.uniqure.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From uniQure N.V.
Seven Potential Blockbuster Approvals To Look Out For In 2023
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
Bayer's High Hopes For Huntington's Gene Therapy As Novartis’s Branaplam Stumbles
When the German major bought AskBio a couple of years ago, one of its assets was a gene therapy for Huntington’s, a devastating disease that leads to complete physical and mental deterioration. That asset, BV-101, is about to enter the clinic.
Sanofi/Sobi’s Next-Gen Factor VIII Therapy BLA Heats Up Biotech-Driven Hemophilia Arms Race
Sanofi/Sobi’s efanesoctocog is in line for US FDA action three months after CSL/uniQure’s gene therapy user fee goal, while BioMarin’s Roctavian resubmission and Novo Nordisk’s concizumab are waiting in the wings.
Freeline Evaluating Options After No Home Run For Hem B Gene Therapy
Freeline’s FLT180a could still prove to be the best-in-class gene therapy for hemophilia B but its cash and time are running out as rivals grow closer to market.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Amsterdam Molecular Therapeutics (AMT)
- Corlieve Therapeutics SAS
- InoCard GmbH
- uniQure Germany GmbH
- uniQure U.S.A.
- uniQure The Netherlands
- uniQure Inc.